Country-wide data stratified by diagnosis and age on demographics and medication use, including switches, of real-world patients with inflammatory rheumatic disease who filled prescription for DMARDs between 8/2016 and 7/2018
| Rheumatoid arthritis (n=27 462) | Psoriatic arthritis (n=8469) | Ankylosing spondylitis (n=6883) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <45 years (n=1933) | 45–65 years (n=10 317) | >65 years (n=15 212) | <45 years (n=1429) | 45–65 years (n=4499) | >65 years (n=2541) | <45 years (n=2145) | 45–65 years (n=3738) | >65 years (n=1000) | ||
| Female gender (%) | 1576 (82) | 8513 (83) | 11 975 (79) | 702 (49) | 2422 (54) | 1404 (55) | 831 (39) | 1500 (40) | 376 (38) | |
| csDMARDs | Methotrexate (%) | 1076 (56) | 6172 (60) | 8321 (55) | 688 (48) | 2474 (55) | 1436 (57) | 315 (15) | 804 (22) | 265 (27) |
| Leflunomide (%) | 329 (17) | 3130 (30) | 5110 (34) | 129 (9) | 749 (17) | 522 (21) | 39 (2) | 131 (4) | 35 (4) | |
| Hydroxychloroquine (%) | 575 (30) | 2846 (28) | 3813 (25) | 31 (2) | 91 (2) | 57 (2) | 26 (1) | 74 (2) | 15 (2) | |
| Other csDMARDs (%) | 205 (11) | 703 (7) | 649 (4) | 382 (27) | 929 (21) | 366 (14) | 166 (8) | 292 (8) | 74 (7) | |
| bDMARDs | Anti-TNF (%) | 934 (34) | 3697 (36) | 4230 (28) | 890 (62) | 2394 (53) | 1095 (43) | 1989 (93) | 3273 (88) | 872 (87) |
| Non-anti-TNF (%) | 336 (17) | 1554 (15) | 2095 (14) | 338 (24) | 972 (22) | 409 (16) | 180 (8) | 410 (11) | 97 (10) | |
| Glucocorticoids (%) | 1073 (56) | 6262 (61) | 10 136 (67) | 472 (33) | 1544(34) | 1008 (40) | 376 (18) | 755 (20) | 271 (27) | |
| Anxiolytics (%) | 323 (17) | 3825 (37) | 7788(51) | 226 (16) | 1525 (34) | 1281 (50) | 309 (14) | 1240 (33) | 475 (48) | |
| Antidepressants (%) | 241 (12) | 2394 (23) | 3988 (26) | 143 (10) | 834 (19) | 591 (23) | 235 (11) | 673 (18) | 208 (21) | |
bDMARD, biologic DMARD; cDMARD, conventional synthetic DMARD; DMARD, disease modifying anti-rheumatic drugs; TNF, tumour necrosis factor.